Chromatics Color Sciences International, Inc. Reports That its ColorMate(R) TLc-BiliTest(R) Receives New CPT (TM) Code from The American Medical Association.

NEW YORK, Nov. 6 /PRNewswire/ --

Chromatics Color Sciences International, Inc. (Nasdaq: CCSI) announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT(TM)) code for use with the Company's ColorMate(R) TLc-BiliTest(R) System, a pain-free, non-invasive device for monitoring bilirubin infant jaundice in newborns. The new code that is listed in CPT 2001 is 88400 bilirubin, total transcutaneous; it does not yet have a fee schedule as the code will not go into effect until January 1, 2001.

Health care providers use the CPT code when reporting medical procedures and services under public and private health insurance programs, and for administrative management in claims processing and developing guidelines for medical care review, according to the AMA.

CCSI has received FDA clearance for the handheld TLc-BiliTest(R) System (TLc-for tender, loving care) for monitoring infant jaundice; the TLc-BiliTest(R) is pain-free for the infant, cost-effective, and provides instant results to the nurse or doctor. CCSI applied for the AMA's CPT code beginning in 1999.

"Hospitals have begun to adopt the use of the TLc-BiliTest monitor developed by Chromatics, " said Brian Fitzpatrick, President and Acting Chief Executive Officer. "The AMA's CPT code will help us continue to introduce the system as a standard of care to hospitals, home health care agencies and physicians for outpatient use."

Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties in this field. The Company has received clearance from the Food and Drug Administration (FDA) for the commercial use of its medical device for the non-invasive monitoring of bilirubinemia in newborn infants by healthcare professionals in hospitals, clinics, pediatrician offices and the home environment. The Company believes its technologies and intellectual properties may also have medical applications in the detection and monitoring of other chromogenic diseases which the Company defines as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. Medical applications, in addition to the non-invasive monitoring of bilirubinemia in newborns, will require additional clinical trials and FDA clearances for commercial use.

The Company's technologies and intellectual properties also have other applications including the scientific color measurement and classification of human skin and certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty-aid and fashion industries.

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the Company's ability to implement its long range business plan for various applications for its technologies, the Company's ability to enter into agreements with additional marketing and distribution partners, the impact of competition, the obtaining and maintaining of any necessary regulatory clearances applicable to applications of the Company's technology, management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including those set forth in its annual report on Form 10-K for the year ended December 31, 1999 and on Form 10-Q for the quarter ended June 30, 2000.